The brain is a common site of disease in patients with ALK+ lung cancer. In this video, Dr. Horn illustrates the line-up of ALK+ treatments and how they work breaking through the blood/brain barrier.

Dr. Taofeek Owonikoko reviews why we often see brain metastases develop as a first or only site of progression in patients with NSCLC and a driver mutation.